A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Catalyst struck a deal Wednesday with Teva that will prevent the generic drugmaker from knocking off Firdapse until 2035.

TL1A – or tumour necrosis factor-like ligand 1A – has become something of a hot topic in IBD, with other candidates ... is matched in phase 3. The TL1A drug would serve as a companion to ...

Technology Networks spoke with Dr. Thomas Dennison, University of Cambridge, to learn more about the advantages of using ...

AstraZeneca shelved its own drug in the class, brazikumab, last year after concluding that the competition in IBD is becoming too fierce. Oral therapies have also staked a claim to the UC market ...

UK scientists have made a major breakthrough while investigating inflammatory bowel disease, which could change the lives of ...

The second pMHC nanomedicine drug candidate, PVT401, is being developed for inflammatory bowel disease by Parvus in partnership with AbbVie. Other pMHC nanomedicine drug candidates are in ...

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

A recent study from the University of Leeds has found that people who regularly take oral steroids for chronic inflammatory ...

The study revealed an intriguing connection between a specific type of calcium channel blocker, known as non-dihydropyridines ...

Researchers have identified a novel genetic risk factor for SARS-CoV-2 infection, providing new insights into the virus's ...